. 2019 Jun 13;13:265. doi: 10.3389/fncel.2019.00265

Table 3.

Effects of I_A channel mRNA expression in brain diseases.

Brain Diseases	Subject	Region	Genetic Basis of I_A Channel	P-Value Control vs. Brain Diseases	References
Alzheimer’s disease	Human patient	Temporal lobe	KCNA4_1	0.099	GSE6834
			KCNA4_2	0.086
			KCNA4_3	0.078
	Human patient	Cerebellum	KCNA4_1	0.070
			KCNC3_1	0.081
			KCND2_1	0.072
	Human patient	Frontal cortex	KCND2_1	0.071	GSE36980
		Temporal cortex	KCND2_1	0.006^**
			KCND3_1	0.043^*
		Hippocampus	KCNA4_1	0.081
			KCND2_1	0.079
			KCND3_1	0.0002^**
Parkinson’s disease	Human post-mortem	Putamen (basal ganglia)	KCNA4_1	0.040^*	GSE20291
			KCNC3_1	0.038^*
			KCNC4_1	0.050
			KCND1_1	0.068
			KCND2_1	0.026^*
			KCND3_1	0.029^*
			KCND3_2	0.034^*
			KCND3_3	0.044^*
			KCND3_4	0.076
		Prefrontal area 9	KCND2_1	0.058	GSE20168
			KCND3_1	0.012^*
Epilepsy	Human patient	Temporal lobe	KCNC3_1	0.0002^**	GSE6834
			KCNC3_2	0.0004^**
			KCNC3_3	0.004^**
Epilepsy	Human patient	Temporal lobe	KCNC3_4	0.048^*	GSE6834
			KCNC4_1	0.030^*
			KCNC4_2	0.059
			KCND2_1	0.102
			KCND3_1	0.008^**
			KCND3_2	0.011^*
Epilepsy (Febrile seizures)	Human patient	Hippocampal CA3	KCNA4_1	0.001^**	GSE28674
			KCNC3_1	0.002^**
			KCND2_1	0.024^*
			KCND2_2	0.029^*
Fragile X syndrome	Mouse (4, 8, 12 weeks)	Cerebellar purkinje cells	KCNA4_1	0.071	GSE57034
			KCND2_1	0.064
			KCND3_1	0.040^*
	Embryo mouse (17–18 days)	Cortex	KCNC3_1	0.045^*	GSE71034
			KCNC4_1	0.058
			KCND3_1	0.002^**
		Cortex primary neuron	KCNA4_1	0.017^*
			KCNA4_2	0.006^**
			KCND2_1	0.030^*
			KCND2_2	0.022^*
			KCND3_1	0.020^*
		Hippocampus primary neurons	KCND2_1	0.074
			KCND3_1	0.072
Tinnitus	Mouse (3 months)	Auditory cortex	KCNA4_1	0.042^*	65
Chronic pain	C57BL/6 X CBA/J mouse (Adult male)	Trigeminal ganglia	KCNC3_1	0.011^*	GSE69619
			KCND1_1	0.016^*
			KCND2_1	0.063
			KCND2_2	0.02^*
Chronic pain	C57BL/6 X CBA/J mouse (Adult male)	Trigeminal ganglia	KCND2_3	0.009^**	GSE69619
			KCND2_4	0.067
			KCND3_1	0.078
Ataxia	Human (Normal vs. Ataxia)	Cerebellum	KCND2_1	0.000000007^**	GSE61019
			KCND3_1	0.015^*
	C57BL/6 mouse (6 weeks)		KCNC4_1	0.046^*	GSE61908
			KCND1_1	0.048^*
	C57BL/6 mouse (6 weeks)		KCND2_1	0.043^*
			KCND3_1	0.042^*
	C57BL/6 mouse (24 months)		KCNC3_1	0.061	GSE55177
			KCND1_1	0.032^*
			KCND2_1	0.08
			KCND3_1	0.009^**
	C57BL/6 mouse (12 months)		KCNC3_1	0.0000007^**
			KCNC3_2	0.00005^**
			KCNC3_3	0.011^*
			KCNC4_1	0.007^**
			KCNC4_2	0.007^**
			KCND2_1	0.079
			KCND3_1	0.007^**
			KCND3_2	0.022^*
			KCND3_3	0.035^*
	C57BL/6 mouse (6 months)		KCNA4_1	0.063
			KCNC3_1	0.002^**
			KCNC4_1	0.043^*
			KCND3_1	0.068
			KCND3_2	0.072
			KCND3_3	0.095

We analyzed human and animal gene expression data from GEO (http://www.ncbi.nlm.nih.gov/geo). Data were analyzed by GEO2R (http://www.ncbi.nlm.nih.gov/geo/geo2r/). GSE6834 and GSE36980 were analyzed for Alzheimer’s disease. GSE20168 and GSE20291 were analyzed for Parkinson’s disease. GSE6834 and GSE28674 were analyzed for epilepsy, GSE57034 and GSE71034 were analyzed for fragile X syndrome. GSE69619 was analyzed for Chronic pain. GSE61019, GSE55177, and GSE61908 were analyzed for Ataxia. Tinnitus data was analyzed by Affymetrix. Statistical significance, ^∗p < 0.05; ^∗∗p < 0.01.